Dominique Bluteau

Dominique Bluteau

Auto-generated profile, based on publicly available information

Dominique Bluteau

Université Paris-Saclay, Gustave Roussy, CNRS UMR9019, F-94805, Villejuif, France

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DBDominique Bluteau
Dominique Bluteau
ABAlessandra Balduini
Alessandra Balduini
NBNathalie Balayn
Nathalie Balayn
MCManuela Currao
Manuela Currao
PNPaquita Nurden
Paquita Nurden
HRHana Raslova
Hana Raslova
Point mutations in the 5′ UTR of ankyrin repeat domain 26 (ANKRD26) are associated with familial thrombocytopenia 2 (THC2) and a predisposition to leukemia. Here, we identified underlying mechanisms of ANKRD26-associated thrombocytopenia. Using megakaryocytes (MK) isolated from THC2 patients and healthy subjects, we demonstrated that THC2-associated mutations in the 5′ UTR of ANKRD26 resulted in loss of runt-related transcription factor 1 (RUNX1) and friend leukemia integration 1 transcription factor (FLI1) binding. RUNX1 and FLI1 binding at the 5′ UTR from healthy subjects led to ANKRD26 silencing during the late stages of megakaryopoiesis and blood platelet development. We showed that persistent ANKRD26 expression in isolated MKs increased signaling via the thrombopoietin/myeloproliferative leukemia virus oncogene (MPL) pathway and impaired proplatelet formation by MKs. Importantly, we demonstrated that ERK inhibition completely rescued the in vitro proplatelet formation defect. Our data identify a mechanism for development of the familial thrombocytopenia THC2 that is related to abnormal MAPK signaling.

1 January 2012 in Nature Communications
Verified
Journal Article
Open access
PDF file
LLLarissa Lordier
Larissa Lordier
DBDominique Bluteau
Dominique Bluteau
AJAbdelali Jalil
Abdelali Jalil
CLCéline Legrand
Céline Legrand
JPJiajia Pan
Jiajia Pan
YCYunhua Chang
Yunhua Chang
Megakaryocytes are unique mammalian cells that undergo polyploidization (endomitosis) during differentiation, leading to an increase in cell size and protein production that precedes platelet production. Recent evidence demonstrates that endomitosis is a consequence of a late failure in cytokinesis associated with a contractile ring defect. Here we show that the non-muscle myosin IIB heavy chain (MYH10) is expressed in immature megakaryocytes and specifically localizes in the contractile ring. MYH10 downmodulation by short hairpin RNA increases polyploidization by inhibiting the return of 4N cells to 2N, but other regulators, such as of the G1/S transition, might regulate further polyploidization of the 4N cells. Conversely, re-expression of MYH10 in the megakaryocytes prevents polyploidization and the transition of 2N to 4N cells. During polyploidization, MYH10 expression is repressed by the major megakaryocyte transcription factor RUNX1. Thus, RUNX1-mediated silencing of MYH10 is required for the switch from mitosis to endomitosis, linking polyploidization with megakaryocyte differentiation.

1 July 2007 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
YCY. Chang
Y. Chang
DBD. Bluteau
D. Bluteau
NDN. Debili
N. Debili
WVW. Vainchenker
W. Vainchenker

8 August 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DBDominique Bluteau
Dominique Bluteau
JMJulien Masliah-Planchon
Julien Masliah-Planchon
CCConnor Clairmont
Connor Clairmont
ARAlix Rousseau
Alix Rousseau
RCRaphael Ceccaldi
Raphael Ceccaldi
JSJean Soulier
Jean Soulier
Fanconi anemia (FA) is a recessive genetic disease characterized by congenital abnormalities, chromosome instability, progressive bone marrow failure (BMF), and a strong predisposition to cancer. Twenty FA genes have been identified, and the FANC proteins they encode cooperate in a common pathway that regulates DNA crosslink repair and replication fork stability. We identified a child with severe BMF who harbored biallelic inactivating mutations of the translesion DNA synthesis (TLS) gene REV7 (also known as MAD2L2), which encodes the mutant REV7 protein REV7-V85E. Patient-derived cells demonstrated an extended FA phenotype, which included increased chromosome breaks and G2/M accumulation upon exposure to DNA crosslinking agents, γH2AX and 53BP1 foci accumulation, and enhanced p53/p21 activation relative to cells derived from healthy patients. Expression of WT REV7 restored normal cellular and functional phenotypes in the patient’s cells, and CRISPR/Cas9 inactivation of REV7 in a non-FA human cell line produced an FA phenotype. Finally, silencing Rev7 in primary hematopoietic cells impaired progenitor function, suggesting that the DNA repair defect underlies the development of BMF in FA. Taken together, our genetic and functional analyses identified REV7 as a previously undescribed FA gene, which we term FANCV.

1 July 2009 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
DBD. Bluteau
D. Bluteau
LLL. Lordier
L. Lordier
ASA. DI Stefano
A. DI Stefano
YCY. Chang
Y. Chang
HRH. Raslova
H. Raslova
WVW. Vainchenker
W. Vainchenker

27 September 2012 in Blood
Verified
Journal Article
Closed access
DBDominique Bluteau
Dominique Bluteau
AGAna C. Glembotsky
Ana C. Glembotsky
ARAnna Raimbault
Anna Raimbault
NBNathalie Balayn
Nathalie Balayn
LGLaure Gilles
Laure Gilles
HRHana Raslova
Hana Raslova
FPD/AML is a familial platelet disorder characterized by platelet defects, predisposition to acute myelogenous leukemia (AML) and germ-line heterozygous RUNX1 alterations. Here we studied the in vitro megakaryopoiesis of 3 FPD/AML pedigrees. A 60% to 80% decrease in the output of megakaryocytes (MKs) from CD34+ was observed. MK ploidy level was low and mature MKs displayed a major defect in proplatelet formation. To explain these defects, we focused on myosin II expression as RUNX1 has been shown to regulate MYL9 and MYH10 in an inverse way. In FPD/AML MKs, expression of MYL9 and MYH9 was decreased, whereas MYH10 expression was increased and the MYH10 protein was still present in the cytoplasm of mature MKs. Myosin II activity inhibition by blebbistatin rescued the ploidy defect of FPD/AML MKs. Finally, we demonstrate that MYH9 is a direct target of RUNX1 by chromatin immunoprecipitation and luciferase assays and we identified new RUNX1 binding sites in the MYL9 promoter region. Together, these results demonstrate that the defects in megakaryopoiesis observed in FPD/AML are, in part, related to a deregulation of myosin IIA and IIB expression leading to both a defect in ploidization and proplatelet formation.